Related references
Note: Only part of the references are listed.Projected Cost-effectiveness of Smoking Cessation Interventions in Patients Hospitalized With Myocardial Infarction
Joseph A. Ladapo et al.
ARCHIVES OF INTERNAL MEDICINE (2011)
A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities
Evelina A. Zimovetz et al.
JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2011)
Ready, Set, Plan, Implement: Executing The Expansion Of Medicaid
Leighton Ku
HEALTH AFFAIRS (2010)
Medicaid Coverage for Tobacco Dependence Treatments in Massachusetts and Associated Decreases in Smoking Prevalence
Thomas Land et al.
PLOS ONE (2010)
Varenicline A Pharmacoeconomic Review of its Use as an Aid to Smoking Cessation
Gillian M. Keating et al.
PHARMACOECONOMICS (2010)
A Longitudinal Study of Medicaid Coverage for Tobacco Dependence Treatments in Massachusetts and Associated Decreases in Hospitalizations for Cardiovascular Disease
Thomas Land et al.
PLOS MEDICINE (2010)
Update on pharmacologic options for smoking cessation treatment
Mitchell Nides
AMERICAN JOURNAL OF MEDICINE (2008)
The impact of prevention on reducing the burden of cardiovascular disease
Richard Kahn et al.
CIRCULATION (2008)
Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation -: A randomized controlled trial
David Gonzales et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures
MB Buntin et al.
JOURNAL OF HEALTH ECONOMICS (2004)
Estimating log models: to transform or not to transform?
WG Manning et al.
JOURNAL OF HEALTH ECONOMICS (2001)
Share Paper
